Review of the NLRP3 Inflammasome Inhibitor RRx-001 Published in the Prestigious Scientific Journal, Drugs
Retrieved on:
星期二, 三月 21, 2023
Neuroprotection, Carcinoma, Translational Research Institute, TRI, Shake it Up Australia Foundation, Acute radiation syndrome, Myocardial infarction, ARS, Inflammasome, Disease, The Michael J. Fox Foundation, Cancer, NLRP3, ALS, Head, Research, Inflammation, Multiple sclerosis, CNS, DSM-IV codes, Associate, Translational Research Institute (Australia), Acute kidney injury, Parkinson's disease, MJFF, Patient, CMR, Pulmonary hypertension, University of Queensland, Alzheimer's disease, Malaria, Pharmaceutical industry
The article is entitled, A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation.
Key Points:
- The article is entitled, A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation.
- Dr. Gordon is an
internationally recognized expert on inflammasome signaling in neurodegenerative diseases. - RRx-001 has been evaluated in multiple independent studies for conditions where immune and inflammasome activation contribute to disease pathology.
- These include cancer, myocardial infarction, pulmonary hypertension, acute kidney injury, acute radiation syndrome (ARS), malaria, multiple sclerosis, Parkinson's disease, and Alzheimer's disease.